{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:25Z","timestamp":1793042785109,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.euroneuro.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T06:58:48Z","timestamp":1706943528000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-0811","authenticated-orcid":false,"given":"Konstantinos N.","family":"Fountoulakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Tohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-7412","authenticated-orcid":false,"suffix":"JR.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2024.01.002_bib0001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-8993(99)01224-X","article-title":"Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release","volume":"825","author":"Aghajanian","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0002","first-page":"120","article-title":"A high-resolution in vivo atlas of the human brain's serotonin system","volume":"37","author":"Beliveau","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0003","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","article-title":"The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity","volume":"95","author":"Bortolozzi","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0004","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1523\/JNEUROSCI.06-11-03177.1986","article-title":"Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain","volume":"6","author":"Boyson","year":"1986","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pnpbp.2006.06.014","article-title":"Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications","volume":"31","author":"Brugue","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0031-6997(25)06780-8","article-title":"International union of pharmacology nomenclature of adrenoceptors","volume":"46","author":"Bylund","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0007","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with Bipolar I or Bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0008","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1471-4159.1994.63020465.x","article-title":"Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor","volume":"63","author":"Cook","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0009","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1461145709990344","article-title":"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis","volume":"13","author":"Cruz","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0012","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0013","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","article-title":"ITI-007 demonstrates brain occupancy at serotonin 5-HT(2)A and dopamine D(2) receptors and serotonin transporters using positron emission tomography in healthy volunteers","volume":"232","author":"Davis","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-006-0333-3","article-title":"5-HT(1B) receptors, ventral orbitofrontal cortex, and aggressive behavior in mice","volume":"185","author":"De Almeida","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0015","unstructured":"FDA, 2018. Caplyta (lumateperone). NDA 209500 multi-disciplinary review and evaluation version date: October 12, 2018. Reference ID: 4537404. Multi-Discipline Review (fda.gov)."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0016","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.euroneuro.2014.11.010","article-title":"The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder","volume":"25","author":"Fountoulakis","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.euroneuro.2024.01.002_bib0017","article-title":"Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?","volume":"10","author":"Fountoulakis","year":"2011","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0018","first-page":"180","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 3: the clinical guidelines","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2023.03.009","article-title":"Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: a hypothesis based on data","volume":"72","author":"Fountoulakis","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl","key":"10.1016\/j.euroneuro.2024.01.002_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00406-012-0323-x","article-title":"Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry","volume":"262","author":"Fountoulakis","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0021","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jad.2011.04.043","article-title":"Receptor targets for antidepressant therapy in bipolar disorder: an overview","volume":"138","author":"Fountoulakis","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/13651501.2018.1470246","article-title":"Personalised and precision psychiatry: what do the CINP bipolar guidelines suggest?","volume":"23","author":"Fountoulakis","year":"2019","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0023","first-page":"1","article-title":"The report of the joint WPA\/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia","author":"Fountoulakis","year":"2020","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-859X-8-16","article-title":"Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review","volume":"8","author":"Fountoulakis","year":"2009","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jad.2010.10.018","article-title":"Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis","volume":"133","author":"Fountoulakis","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0026","first-page":"196","article-title":"The International College of Neuropsychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 4: unmet needs in the treatment of bipolar disorder and recommendations for future research","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0027","first-page":"121","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 2: review, grading of the evidence, and a precise algorithm","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0028","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ijnp\/pyz064","article-title":"The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder","volume":"23","author":"Fountoulakis","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0029","first-page":"98","article-title":"The International College of Neuropsychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 1: background and methods of the development of guidelines","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.107.121715","article-title":"ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models","volume":"322","author":"Gardell","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0031","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0893-133X(00)00087-7","article-title":"Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex","volume":"22","author":"Gessa","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0032","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1060028020936597","article-title":"Lumateperone: a novel antipsychotic for schizophrenia","volume":"55","author":"Greenwood","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.npp.1380111","article-title":"Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain","volume":"11","author":"Hall","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0034","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1523\/JNEUROSCI.0792-06.2006","article-title":"Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking","volume":"26","author":"Hallett","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0035","doi-asserted-by":"crossref","unstructured":"Harvey, J.A., 2003. Role of the serotonin 5-HT(2A) receptor in learning. Learning & memory (Cold Spring Harbor, N.Y.) 10, 355\u2013362.","DOI":"10.1101\/lm.60803"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0036","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0031-6997(25)06845-0","article-title":"International union of pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update","volume":"47","author":"Hieble","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0037","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00213-018-5042-1","article-title":"The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug","volume":"235","author":"Jalal","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0038","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0039","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnsys.2011.00028","article-title":"Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum","volume":"5","author":"Jocoy","year":"2011","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40263-020-00752-2","article-title":"Targeting serotonin 5-HT(2A) receptors to better treat schizophrenia: rationale and current approaches","volume":"34","author":"Kantrowitz","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0041","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0042","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1358\/dot.2018.54.12.2899443","article-title":"Lumateperone: a new treatment approach for neuropsychiatric disorders","volume":"54","author":"Kumar","year":"2018","journal-title":"Drugs Today"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0043","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm401958n","article-title":"Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0044","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0046","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1523\/JNEUROSCI.10-08-02587.1990","article-title":"Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis","volume":"10","author":"Mansour","year":"1990","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0047","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.npp.1300762","article-title":"The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine","volume":"30","author":"Marek","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0048","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(01)00199-3","article-title":"A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex","volume":"105","author":"Marek","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0049","doi-asserted-by":"crossref","unstructured":"Martin, P., Waters, N., Schmidt, C.J., Carlsson, A., Carlsson, M.L., 1998. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm. (Vienna, Austria: 1996) 105, 365\u2013396.","DOI":"10.1007\/s007020050064"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0050","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14739","article-title":"The efficacy of lumateperone in patients with bipolar depression with mixed features","volume":"84","author":"McIntyre","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0051","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euroneuro.2022.12.012","article-title":"The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: secondary and post hoc analyses","volume":"68","author":"McIntyre","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0052","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1139\/jpn.0709","article-title":"Imaging the serotonin transporter during major depressive disorder and antidepressant treatment","volume":"32","author":"Meyer","year":"2007","journal-title":"J. Psychiatry Neurosci.: JPN"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0053","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1139\/jpn.0847","article-title":"Serotonin2A receptor binding potential in people with aggressive and violent behaviour","volume":"33","author":"Meyer","year":"2008","journal-title":"J. Psychiatry Neurosci.: JPN"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0054","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0306-4522(02)00580-8","article-title":"Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex","volume":"116","author":"Miner","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0056","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518779829","article-title":"Physiological and functional basis of dopamine receptors and their role in neurogenesis: possible implication for Parkinson's disease","volume":"12","author":"Mishra","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0057","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","article-title":"Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists","volume":"493","author":"Moreno","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0058","article-title":"Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences","author":"Munayco Maldonado","year":"2023","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0059","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/acps.13618","article-title":"Correlation between emotion dysregulation and mood symptoms of bipolar disorder: a systematic review and meta-analysis","volume":"148","author":"Oliva","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0060","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1523\/JNEUROSCI.12-10-03729.1992","article-title":"D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease","volume":"12","author":"Paul","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0061","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1176\/appi.ajp.2007.07091513","article-title":"Aripiprazole's receptor pharmacology and extrapyramidal side effects","volume":"165","author":"Poyurovsky","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0062","series-title":"Serotonin Receptors in Neurobiology","article-title":"Serotonin 2A (5-HT(2A)) receptor function: ligand-dependent mechanisms and pathways","author":"Raote","year":"2007"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0063","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2009.00089.x","article-title":"Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials","volume":"17","author":"Rosa","year":"2011","journal-title":"CNS. Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0064","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.biopsych.2010.03.013","article-title":"Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients","volume":"67","author":"Rosell","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2024.01.002_bib0065","first-page":"S1","article-title":"Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence","volume":"10","author":"Sartorius","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0066","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00213-005-2198-2","article-title":"Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder","volume":"181","author":"Seager","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0067","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2004.02.012","article-title":"Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity","volume":"55","author":"Seager","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0068","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1523\/JNEUROSCI.18-24-10297.1998","article-title":"A dopamine\/D1 receptor\/protein kinase A\/dopamine- and cAMP-regulated phosphoprotein (Mr 32kDa)\/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor","volume":"18","author":"Snyder","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0069","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0070","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bdi.13310","article-title":"Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized placebo-controlled clinical trial","volume":"25","author":"Suppes","year":"2023","journal-title":"Bipolar. Disord."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0071","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1124\/jpet.103.052597","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment","volume":"306","author":"Tarazi","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0072","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.06.009","article-title":"Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: a dopamine D(1) receptor dependent mechanism","volume":"62","author":"Titulaer","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0073","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jad.2013.01.022","article-title":"Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies","volume":"149","author":"Tohen","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0074","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1192\/bjp.bp.112.108357","article-title":"Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression","volume":"201","author":"Tohen","year":"2012","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13081193","article-title":"Novel compounds in the treatment of schizophrenia-a selective review","volume":"13","author":"Tsapakis","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0076","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1523\/JNEUROSCI.21-10-03572.2001","article-title":"5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells","volume":"21","author":"Van de Kar","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0077","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/NSS.S6849","article-title":"Role of 5-HT2A receptor antagonists in the treatment of insomnia","volume":"2","author":"Vanover","year":"2010","journal-title":"Nat. Sci. Sleep"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0078","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0079","doi-asserted-by":"crossref","first-page":"e07","DOI":"10.4088\/JCP.8125tx4c","article-title":"Long-term treatment of bipolar depression and other issues","volume":"71","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0080","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.4088\/JCP.8125tx3c","article-title":"Role of antidepressants in bipolar depression","volume":"71","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0081","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/JCP.0b013e3181f15849","article-title":"Treatment options for bipolar depression: a systematic review of randomized, controlled trials","volume":"30","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0082","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4088\/JCP.v63n0607","article-title":"A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers","volume":"63","author":"Vieta","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0083","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2019.1695778","article-title":"An evaluation of lumateperone tosylate for the treatment of schizophrenia","volume":"21","author":"Vyas","year":"2020","journal-title":"Expert. Opin. PharmacOther"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0084","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0091-3057(00)00483-4","article-title":"Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats","volume":"68","author":"Wadenberg","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0085","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002130000466","article-title":"Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats","volume":"150","author":"Wadenberg","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0086","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0924-977X(96)00035-1","article-title":"Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat","volume":"6","author":"Wadenberg","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0087","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1523\/JNEUROSCI.22-07-02843.2002","article-title":"The physiological role of 5-HT2A receptors in working memory","volume":"22","author":"Williams","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0088","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-5618.2007.00528.x","article-title":"Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder","volume":"10","author":"Wiste","year":"2008","journal-title":"Bipolar. Disord."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0089","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0361-9230(99)00278-6","article-title":"Cellular localization of serotonin(2A) (5HT(2A)) receptors in the rat brain","volume":"51","author":"Xu","year":"2000","journal-title":"Brain Res. Bull."},{"issue":"Suppl 5","key":"10.1016\/j.euroneuro.2024.01.002_bib0090","first-page":"40","article-title":"Atypical antipsychotics in bipolar depression: potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0091","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","article-title":"Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis","volume":"10","author":"Yildiz","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0092","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0006-3223(94)91201-7","article-title":"Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder","volume":"35","author":"Young","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0093","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.euroneuro.2021.05.001","article-title":"Do cariprazine and brexpiprazole cause impulse control symptoms? A case\/non-case study","volume":"50","author":"Zazu","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.01.002_bib0094","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1523\/JNEUROSCI.22-21-09635.2002","article-title":"Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI","volume":"22","author":"Zhang","year":"2002","journal-title":"J. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24000154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24000154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:07:23Z","timestamp":1760378843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24000154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":94,"alternative-id":["S0924977X24000154"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.01.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}